Med BioGene’s lead test under development is LungExpress Dx, a proprietary 15-gene signature to improve upon staging for identifying those patients with early-stage non-small-cell lung cancer who, following surgical removal of their tumor, are at a higher and lower risk of mortality.  In an initial study, published in the Journal of Clinical Oncology, of patient specimens from the National Cancer Institute of Canada Clinical Trials Group JBR.10 trial, patients classified by LungExpress Dx as higher risk benefited from adjuvant chemotherapy, and those classified as lower risk did not benefit, and may have experienced a detrimental effect, from adjuvant chemotherapy.  LungExpress Dx is being developed to provide better-informed and personalized treatment decisions to assist in the selection of patients for adjuvant chemotherapy.

Med BioGene and Precision Therapeutics have partnered for the global commercialization of LungExpress Dx.  For more information on Precision Therapeutics, please see www.precisiontherapeutics.com.